Background Levofloxacin (LVFX) 
Introduction

Levofloxacin (LVFX) is widely used in the fields
Patients and Methods
Patients
Seven patients with hematological malignancies treated at Kyoto Prefectural University of Medicine received LVFX 200 mg, b.i.d., as a prophylaxis for febrile neutropenia (FN). Only one patient received 100 mg, t.i.d. (No. 8). After in-
Drug concentration
All patients' data are described in Table 2 and the drug concentration curve is depicted in Fig. 1 . (15, 16) .
F i g u r e 1 . T h e c o n c e n t r a t i o n d r u g c u r v e o f l e v o f l o x a c i n i n p e r i p h e r a l b l o o d .
T a b l e 3 . P o p u l a t i o n P h a r ma c o k i n e t i c P a r a me t e r s
Population pharmacokinetics
NONMEM analysis presented population pharmacokinetics data (RSE%) as follows: distribution of volume (Vd
